莱茵生物(002166.SZ)：德福资本与莱茵生物都高度看好天然健康成分这一细分赛道

Core Viewpoint - The collaboration between Rhein Biotech and Defo Capital is driven by a shared strategic vision and mutual recognition of the potential in the natural health ingredients sector [1] Group 1: Strategic Alignment - Both Defo Capital and Rhein Biotech have a strong belief in the natural health ingredients niche, which forms the foundation of their partnership [1] - The strategic alignment and shared philosophy between the two entities are key drivers for the collaboration [1] Group 2: Comprehensive Advantages - Rhein Biotech has over 20 years of industry experience, establishing a solid industry position and comprehensive advantages that attracted Defo Capital [1] - The company boasts a well-rounded industrial layout, robust production capacity, leading production technology, and a global sales network, ensuring a strong operational foundation [1] - Rhein Biotech possesses systematic capabilities in product selection, development, and incubation, enabling efficient transformation from concept to market [1] Group 3: Continuous Business Upgrades - The company demonstrates an internal drive for continuous business upgrades and technological iterations, maintaining a keen awareness of technological advancements [1] - Rhein Biotech has proactively ventured into cutting-edge fields such as synthetic biology and formulation applications, successfully achieving technological upgrades [1] - The company is actively exploring diverse application scenarios, including animal feed and pet nutrition, showcasing its growth vitality and potential [1]